# A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

> **NCT02783573** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 1722 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Lanabecestat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02783573
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-01
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-09-28
- **Target enrollment:** 1722 (ACTUAL)
- **Why stopped:** An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.
- **Last updated:** 2019-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02783573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02783573, "A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02783573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*